Cougar Biotechnology Appoints Dr. Russell Ellison to Board of Directors.

LOS ANGELES -- Cougar Biotechnology, Inc., a publicly held biotechnology company, today announced the appointment of Russell H. Ellison, M.D., MSc, to the Company's Board of Directors. Dr. Ellison is currently the Vice President of Clinical Development of Fibrogen, Inc., a privately held biotechnology-based drug discovery company using its expertise in the fields of tissue fibrosis, connective tissue growth factor (CTGF), and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for fibrotic disorders, diabetic complications, anemia, ischemic disease, cancer, and other areas of unmet medical need.

Prior to Fibrogen, Dr. Ellison was the Vice President of Medical Affairs and Chief Medical Officer of Sanofi-Synthelabo, where he was responsible for several key oncology products including Eloxatin (oxaliplatin) for colorectal cancer and Eligard (leuprolide acetate for injectable suspension) for prostate cancer. Dr. Ellison also served as Vice President, Medical Affairs, and Chief Medical Officer of Hoffmann La Roche, Inc. from 1997 through 2002 and held several drug development positions with Roche Canada from 1990 to 1997. Dr. Ellison holds an M.D. from the University of British Columbia and an MSc (with distinction) from The London School of Tropical Medicine and Hygiene.

"We are pleased to be able to have an independent director with Russell's extensive clinical background joining the Cougar Board of Directors," said Dr. Arie Belldegrun, M.D., FACS, Vice Chairman of the Board of Directors of Cougar Biotechnology. Alan H. Auerbach, Chief Executive Officer and President of Cougar Biotechnology, added, "Russell's broad clinical development experience will be extremely valuable to the Cougar Board of Directors at this important time in the Company's growth. We look forward to the contributions that Russell will make to the Cougar Board."

About Cougar Biotechnology

Cougar Biotechnology, Inc. is a Los Angeles-based publicly held biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, a targeted inhibitor of the 17-alpha hydroxylase/c17,20 lyase enzyme which is currently being tested in a Phase I clinical trial in prostate cancer; CB3304, an inhibitor of microtubule dynamics which is currently in a Phase I trial in hematological malignancies; and CB1089, an analog of vitamin D which has been clinically tested in a number of solid tumor types.

Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.

This press release contains forward-looking statements that involve risks and uncertainties that could cause Cougar's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Cougar's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Cougar's product candidates, the risk that the results of clinical trials may not support Cougar's claims, Cougar's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 7, 2006. Cougar assumes no obligation to update these statements, except as required by law.